Skip to main content

Teva Pharmaceutical Industries (NYSE:TEVA) Lowered to Neutral at UBS Group

Tuesday, May 4, 2021 | MarketBeat

Teva Pharmaceutical Industries (NYSE:TEVA) was downgraded by UBS Group from a "buy" rating to a "neutral" rating in a research note issued on Tuesday, Briefing.com reports. They presently have a $11.00 price target on the stock, down from their prior price target of $15.00. UBS Group's price target would indicate a potential upside of 1.76% from the company's previous close.

Several other brokerages have also issued reports on TEVA. TheStreet raised Teva Pharmaceutical Industries from a "d+" rating to a "c-" rating in a research note on Monday, April 5th. JPMorgan Chase & Co. reissued a "hold" rating and set a $10.00 price objective on shares of Teva Pharmaceutical Industries in a research report on Sunday, March 14th. One analyst has rated the stock with a sell rating, nine have issued a hold rating and three have issued a buy rating to the stock. Teva Pharmaceutical Industries presently has an average rating of "Hold" and an average target price of $11.58.

NYSE TEVA opened at $10.81 on Tuesday. The business has a fifty day moving average price of $11.02 and a two-hundred day moving average price of $10.61. The stock has a market capitalization of $11.81 billion, a PE ratio of -2.94, a PEG ratio of 0.87 and a beta of 1.49. Teva Pharmaceutical Industries has a fifty-two week low of $8.44 and a fifty-two week high of $13.30. The company has a debt-to-equity ratio of 2.22, a current ratio of 1.00 and a quick ratio of 0.63.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings results on Wednesday, April 28th. The company reported $0.63 EPS for the quarter, topping analysts' consensus estimates of $0.55 by $0.08. The company had revenue of $3.98 billion during the quarter, compared to analysts' expectations of $4.04 billion. Teva Pharmaceutical Industries had a positive return on equity of 19.32% and a negative net margin of 24.17%. Teva Pharmaceutical Industries's revenue was down 8.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.76 EPS. As a group, sell-side analysts expect that Teva Pharmaceutical Industries will post 2.42 earnings per share for the current year.

In other Teva Pharmaceutical Industries news, insider Mark Sabag sold 127,244 shares of the business's stock in a transaction that occurred on Tuesday, March 16th. The stock was sold at an average price of $11.22, for a total transaction of $1,427,677.68. Following the completion of the sale, the insider now directly owns 20,598 shares of the company's stock, valued at approximately $231,109.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.56% of the company's stock.

Institutional investors have recently bought and sold shares of the business. IHT Wealth Management LLC purchased a new stake in shares of Teva Pharmaceutical Industries during the third quarter valued at approximately $101,000. Jeppson Wealth Management LLC purchased a new stake in Teva Pharmaceutical Industries during the third quarter valued at about $26,000. Mercer Global Advisors Inc. ADV boosted its position in Teva Pharmaceutical Industries by 262.2% during the third quarter. Mercer Global Advisors Inc. ADV now owns 78,518 shares of the company's stock worth $707,000 after purchasing an additional 56,839 shares during the period. Bellecapital International Ltd. increased its stake in shares of Teva Pharmaceutical Industries by 63.1% in the fourth quarter. Bellecapital International Ltd. now owns 26,100 shares of the company's stock worth $252,000 after purchasing an additional 10,100 shares in the last quarter. Finally, DNB Asset Management AS raised its position in shares of Teva Pharmaceutical Industries by 25.3% in the fourth quarter. DNB Asset Management AS now owns 100,921 shares of the company's stock valued at $974,000 after purchasing an additional 20,354 shares during the period. 51.20% of the stock is currently owned by hedge funds and other institutional investors.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

Featured Article: What is the float in trading stocks?

Analyst Recommendations for Teva Pharmaceutical Industries (NYSE:TEVA)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Featured Article: What is the Difference Between Common Shares and Convertible Shares?


7 Penny Stocks That Don’t Care About Robinhood

By the time you read this Vladimir Tenev, the CEO of the trading app Robinhood, will be testifying in front of Congress. The company’s role in the GameStop (NYSE:GME) short squeeze will be called into question.

However, the real issue at stake is the right of traders to buy and sell the equities of their choice. In the case of Robinhood, some traders are buying a lot of penny stocks. While definitions vary, penny stocks are generally considered stocks that are trading for less than $10 per share. These stocks are largely ignored by the investment community.

One reason is that many of these stocks are cheap for a reason. For example, the company may have a business model that is out of date. In other cases, they operate in a very small, niche market that doesn’t drive a lot of revenue.

And most of these stocks are ignored by the investment community. They simply aren’t considered significant enough to spend time debating.

But some penny stocks do have the attention of Wall Street. And they’re being largely ignored by the day trading community. The focus of this special presentation is to direct you to penny stocks that have a story that the “smart money” thinks will eventually be trading at much higher prices.

And that’s why you should be looking at them now.

View the "7 Penny Stocks That Don’t Care About Robinhood".


MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.